Visirna Therapeutics
Shanghai
About Visirna Therapeutics
Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $60.0M
- Funding stage: Seed
- Last round: Seed (Apr 2022)
- Website: visirna.com
- Phone: +86 021-6107 5030
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/visirna-therapeutics-15357 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.